Page last updated: 2024-12-06

ceforanide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ceforanide is a broad-spectrum cephalosporin antibiotic that was first synthesized in the 1970s. It is a prodrug that is converted to its active form in the body. It is active against a wide range of Gram-positive and Gram-negative bacteria, including penicillinase-producing strains. Ceforanide is effective in the treatment of a variety of infections, including respiratory tract infections, skin and soft tissue infections, and urinary tract infections. It is also used to treat some types of meningitis. Ceforanide is administered intravenously or intramuscularly. It is well-absorbed after intravenous administration and has a long half-life. Ceforanide is generally well-tolerated. The most common side effects are nausea, vomiting, and diarrhea. It is rarely associated with serious side effects, such as allergic reactions, but can cause nephrotoxicity. Ceforanide is studied to understand its mechanism of action and efficacy, as well as to develop new cephalosporin antibiotics with improved properties.'

ceforanide: RN given refers to (6R-(trans))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID43507
CHEMBL ID1201046
CHEBI ID3495
SCHEMBL ID122072
MeSH IDM0059859

Synonyms (90)

Synonym
ceforanido
ceforanidum
chebi:3495 ,
(6r,7r)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1h-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
BRD-K37848908-001-03-1
(6r,7r)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1h-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
bl-s786
PRESTWICK3_000470
BPBIO1_000638
NCGC00016897-01
cas-60925-61-3
PRESTWICK2_000470
(6r,7r)-7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
precef
BSPBIO_000580
AB00513845
ceforanide
60925-61-3
C06884
DB00923
7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1h-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid
7-[o-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1h-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid
ceforanide (usp/inn)
D00259
precef (tn)
(6r,7r)-7-(2-(alpha-amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ceforanido [inn-spanish]
(6r-trans)-7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-trans)-
bl-s 786
7-(o-(aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid
ceforanidum [inn-latin]
PRESTWICK0_000470
SPBIO_002519
PRESTWICK1_000470
nsc-760049
CHEMBL1201046
HMS1569M22
HMS2096M22
7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
tox21_110670
dtxcid402760
dtxsid1022760 ,
unii-8m1yf8951v
nsc 760049
8m1yf8951v ,
ceforanide [usan:usp:inn:ban]
ceforanide [vandf]
ceforanide [orange book]
ceforanide [inn]
ceforanide [mi]
ceforanide [mart.]
(6r,7r)-7-[2-(alpha-amino-o-tolyl)acetamido]-3-[[[1-(carboxymethyl)-1h-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ceforanide [usan]
ceforanide [who-dd]
ceforanide [usp-rs]
ceforanide [usp impurity]
CCG-220470
SCHEMBL122072
(6r,7r)-7-{2-[2-(aminomethyl)phenyl]acetamido}-3-({[1-(carboxymethyl)-1h-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SR-01000872614-2
AKOS027427040
SR-01000872614-3
sr-01000872614
HMS3713M22
HY-B1297
Q5057287
AS-15783
NCGC00179514-05
CS-0013066
D81832
A913663
S5081
ceforanide(200mg)
(6r,7r)-7-(2-(2-(aminomethyl)phenyl)acetamido)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid
gtpl12218
(6r,7r)-7-((2-(2-(aminomethyl)phenyl)acetyl)amino)-3-((1-(carboxymethyl)tetrazol-5-yl)sulfanylmethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
7-(alpha-(2-aminomethylphenyl)acetamido)-3-((1-carboxymethyltetrazol-5-ylthio)methyl)-3-cephem-4-carboxylic acid
cefaronide
ceforanidum (inn-latin)
j01dc11
ceforanida
7beta-(2-(aminomethyl)phenyl)acetamido-3-((1-(carboxymethyl)-1h-tetrazol-5-yl)sulfanyl)methyl-3,4-didehydrocepham-4-carboxylic acid
ceforanide (usp-rs)
ceforanide (usp impurity)
ceforanide (usan:usp:inn:ban)
ceforanido (inn-spanish)
(6r,7r)-7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1h-tetrazol-5-yl)sulfanyl)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ceforanide (mart.)
EN300-7408761

Research Excerpts

Overview

Ceforanide appears to be a safe, efficacious, convenient, and relatively inexpensive drug for treating staphylococcal endocarditis in parenteral drug abusers. Ceforanid is a 'second generation' cephalosporin administered intravenously or intramuscularly.

ExcerptReferenceRelevance
"Ceforanide appears to be a safe, efficacious, convenient, and relatively inexpensive drug for treating staphylococcal endocarditis in parenteral drug abusers."( Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers.
Arcey, SM; Greenman, RL; Gutterman, DA; Zweig, RM, 1984
)
1.29
"Ceforanide is a new cephalosporin with a longer elimination half-life than any currently available cephalosporin. "( Ceforanide: antibacterial activity, pharmacology, and clinical efficacy.
Barriere, SL; Mills, J,
)
3.02
"Ceforanide is a new (parenteral) long-acting cephalosporin with antimicrobial activity comparable to those of other second-generation cephalosporins. "( Ceforanide and cefazolin therapy of pneumonia: comparative clinical trial.
Greenberg, SB; Martin, RR; Quinones, FJ; Wallace, RJ, 1981
)
3.15
"Ceforanide proved to be a useful agent in the treatment of right-sided endocarditis due to susceptible S."( Evaluation of ceforanide as treatment for staphylococcal and streptococcal endocarditis.
Cooper, RH; Joseph, WP; Mills, J; Savitch, CB, 1981
)
1.34
"Ceforanide (BL-S786R) is a new, broad-spectrum, parenteral cephalosporin. "( Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
Hottendorf, GH; Lee, FH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1980
)
1.99
"Ceforanide (BL-S 786) is a new long-acting parenteral cephalosporin which has the major pharmacologic advantage of requiring only twice a day dosage. "( Ceforanide (BL-S786) in the treatment of community-acquired bacterial pneumonia.
Greenberg, SB; Martin, RR; Wallace, RJ, 1979
)
3.15
"Ceforanide is a 'second generation' cephalosporin administered intravenously or intramuscularly. "( Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Campoli-Richards, DM; Lackner, TE; Monk, JP, 1987
)
3.16

Effects

ExcerptReferenceRelevance
"Ceforanide also has been shown to be as effective as cephalothin or cephaloridine when given prophylactically for vaginal hysterectomy."( Ceforanide: antibacterial activity, pharmacology, and clinical efficacy.
Barriere, SL; Mills, J,
)
2.3

Actions

ExcerptReferenceRelevance
"Ceforanide (CEF) can inhibit tubercle bacilli in vitro but has been found ineffective clinically."( Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages.
Crowle, AJ; May, MH; Sbarbaro, JA, 1988
)
1.29

Treatment

ExcerptReferenceRelevance
"Treatment with ceforanide, a new second-generation cephalosporin with high intrinsic activity against Klebsiella, and possessing a long half-life, was used as outpatient treatment."( Treatment of scleroma with ceforanide.
Barton, SM; Cone, LA; Woodard, DR, 1987
)
0.91

Pharmacokinetics

The pharmacokinetic of ceforanide, a new parenteral cephalosporin antibiotic, were examined at intravenous and intramuscular doses of 250, 500, and 1,000 mg in healthy male volunteers. No significant differences were observed between single and multiple doses of the drug.

ExcerptReferenceRelevance
" No significant differences were observed in plasma-renal pharmacokinetic parameters between single and multiple doses of ceforanide."( Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.
Glick, A; Hottendorf, GH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1979
)
0.72
" Ceforanide half-life varied with the ages of the patients: in 1- to 2-year-old children, in half-life was significantly shorter (1."( Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.
Bawdon, RE; Buckley, JA; Dajani, AS; Pfeffer, M; Smyth, RD; Thirumoorthi, MC; Van Harken, DR, 1982
)
1.45
"The pharmacokinetic of ceforanide, a new parenteral cephalosporin antibiotic, were examined at intravenous and intramuscular doses of 250, 500, and 1,000 mg in healthy male volunteers."( Pharmacokinetics of ceforanide.
Ghezzi, A; La Rosa, F; Pfeffer, M; Prenna, M; Ripa, S, 1982
)
0.9
" Pharmacokinetic properties were determined in rats (100 mg/kg), rabbits (30 mg/kg), dogs (25 mg/kg), and humans (2 g or 30 mg/kg) and compared with equivalent single doses of cefazolin."( Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
Hottendorf, GH; Lee, FH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1980
)
0.54
" The plasma half-life (T 1/2) of the drug was 19."( Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.
Berman, SJ; Boughton, WH; Hess, JR; Musgrave, JE; Siemsen, AM; Sugihara, JG; Wong, EG, 1980
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The elimination half-life of ceforanide is about 3 hrs in patients with normal renal function. This allows twice daily dosing for the majority of patients. The slower elimination kinetics are indicative of the potential for a longer dosing interval and more effective antibiotic therapy.

ExcerptRelevanceReference
" It has no advantage over other cephalosporins with regard to spectrum of antibacterial activity, but has a longer half-life than other second generation cephalosporins, except cefonicid, and can be administered according to a twice daily dosage schedule."( Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Campoli-Richards, DM; Lackner, TE; Monk, JP, 1987
)
1.72
" The sustained plasma and bone levels achieved with ceforanide obviate the need for intraoperative dosing necessary with other agents."( Comparison of ceforanide and cephalothin prophylaxis in patients undergoing total joint arthroplasty.
Brause, BD; Hirsch, JC; Roberts, RB; Salvati, EA; Soave, R, 1986
)
0.88
" Smaller doses, longer dosing intervals and, potentially, a reduction in total drug cost may be the real advantage of these agents."( Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.
Polk, RE; Tartaglione, TA, 1985
)
0.51
" The elimination half-life of ceforanide is about 3 hrs in patients with normal renal function; this allows twice daily dosing for the majority of patients."( Ceforanide: antibacterial activity, pharmacology, and clinical efficacy.
Barriere, SL; Mills, J,
)
1.86
" Dosage recommendations for 1- to 2 year-old children are presented."( Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.
Bawdon, RE; Buckley, JA; Dajani, AS; Pfeffer, M; Smyth, RD; Thirumoorthi, MC; Van Harken, DR, 1982
)
0.54
" Dosing recommendations for patients with renal insufficiency are provided."( Ceforanide kinetics in renal insufficiency.
Alford, RH; Hawkins, SS; Pfeffer, M; Smyth, RD; Stone, WJ, 1981
)
1.71
" The slower elimination kinetics of ceforanide are indicative of the potential for a longer dosing interval and more effective antibiotic therapy as compared with available cephalosporins."( Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.
Hottendorf, GH; Lee, FH; Pfeffer, M; Smyth, RD; Van Harken, DR, 1980
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-199053 (80.30)18.7374
1990's4 (6.06)18.2507
2000's1 (1.52)29.6817
2010's4 (6.06)24.3611
2020's4 (6.06)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.55 (24.57)
Research Supply Index4.48 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (17.57%)5.53%
Reviews6 (8.11%)6.00%
Case Studies2 (2.70%)4.05%
Observational1 (1.35%)0.25%
Other52 (70.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]